Latest Financial Position News

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

LCL Resources has renegotiated its sale option agreement with Tiger Gold Corp, increasing the total consideration to $14 million and removing the 'Stay Private' clause. The revised terms will be presented for shareholder approval at the upcoming AGM.

Bastion Minerals has made significant strides in its Canadian copper exploration portfolio, progressing towards a maiden JORC Mineral Resource Estimate for the ICE Copper Project while completing a modest capital raise and refreshing its board.

Boss Energy reports a successful ramp-up to commercial production at its Honeymoon uranium mine, backed by a robust $229 million cash position and promising growth at its US Alta Mesa project.

Kelsian Group signals a cautious FY25 outlook with EBITDA tracking at the lower end of guidance, while advancing strategic tourism divestments and securing key contract renewals.

MyEco Group has secured $1.6 million through unsecured convertible notes to support a strategic operational restructure aimed at reducing costs and scaling production. This capital raise complements existing cash reserves and aims to improve margins while minimising shareholder dilution.

Brightstar Resources outlines an ambitious growth plan targeting over 200,000 ounces of gold production annually by 2029, driven by expansions at Laverton and Menzies hubs and accelerated development of the Sandstone project.

SPC Global Holdings confirms FY2025 pro forma EBITDA guidance of A$29 million, driven by strong early post-merger performance and strategic initiatives including site consolidation and leadership renewal.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Chalice Mining reports significant metallurgical improvements at its Gonneville Project, boosting metal recoveries and revealing a promising iron byproduct that could enhance project economics.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.